42.

41. Edgar Petrosyan, Jawad Fares, Luis G. Fernandez, Ragini Yeeravalli, Crismita Dmello, Joseph T. Duffy, Peng Zhang, Catalina Lee-Chang, Jason Miska, Atique U. Ahmed, Adam M. Sonabend, Irina V. Balyasnikova, Amy B. Heimberger, Maciej S. Lesniak; Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Mol Cancer Res 1 May 2023; 21 (5): 389–396. https://doi.org/10.1158/1541-7786.MCR-22-0920

40. Zhang, P., Rashidi, A., Zhao, J. et al. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun 14, 1610 (2023). https://doi.org/10.1038/s41467-023-37328-9

39. Crismita Dmello, Junfei Zhao, Li Chen, Andrew Gould, Brandyn Castro, Victor A Arrieta, Daniel Y Zhang, Kwang-Soo Kim, Deepak Kanojia, Peng Zhang, Jason Miska, Ragini Yeeravalli, Karl Habashy, Ruth Saganty, Seong Jae Kang, Jawad Fares, Connor Liu, Gavin Dunn, Elizabeth Bartom, Matthew J Schipma, Patrick D Hsu, Mahmoud S Alghamri, Maciej S Lesniak, Amy B Heimberger, Raul Rabadan, Catalina Lee-Chang, Adam M Sonabend. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun 14, 1566 (2023). https://doi.org/10.1038/s41467-023-36878-2

38. Miska J and NS Chandel. Targeting fatty acid metabolism in glioblastoma. J Clin Invest. 2023;133(1):e163448. https://doi.org/10.1172/JCI163448.

37. Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, Lee-Chang C, Miska J , Lesniak MS, Gottschalk S, and Balyasnikova IV. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. Journal for ImmunoTherapy of Cancer 2023;11:e006239. doi: 10.1136/jitc-2022-006239

36. Billingham, L.K., Stoolman, J.S., Vasan, K. et al. Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. Nat Immunol 23, 692–704 (2022). https://doi.org/10.1038/s41590-022-01185-3

35. Miska J, Rashidi A, Lee-Chang C, Gao P, Lopez-Rosas A, Zhang P, Burga RA, Castro B, Xiao T, Han Y, Hou D, Sampat S, Cordero A, Stoolman JS, Horbinski CM, Burns M, Reshetnyak YK, Chandel NS, and Lesniak MS. Polyamines drive myeloid-cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma Science Advances. (2021) 7, eabc8929

34. Shireman J, Atashi F, Lee G, Ali ES, Saathoof MR, Park CH, Basiwala S, Miska J, Lesniak MS, CD James, Stupp R, Kumthekar, Horbinski CM, Ben-Sahra I, and Ahmed AU. De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain (2021) –In Press

33. Caragher S, Miska J*, Shireman J, Park CH, Muroski ME, Lesniak MS and Ahmed AU,. Temozolomide Treatment Increases Fatty Acid Uptake in Glioblastoma Stem Cells. Cancers. (2020) 12(11), 3126

32. Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, Jusue-Torres I, Xiao T, Arrieta VA, Zhang DY, Lopez-Rosas A, Han Y, Sonabend AM, Horbinski CM, Stupp R, Balyasnikova IV, and Lesniak MS. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. Journal of Experimental Medicine. (2020) 218(1):e20200913

31. Kanojia D, Panek WK, Cordero A, Fares J, Xiao A, Savchuk S, Kumar K, Pituch KC, Miska J, Zhang P, Kam K-L, Horbinski CM, Balyasnikova IV, Ahmed AU, and Lesniak MS. BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine. Science Translational Medicine. (2020) 12(558):eaax2879

30. Poropatich K, Dominguez D, Chan W-C, Andrade J, Zha Y, Brian Wray, Miska J, Qin L, Cole L, Coates S, Patel U, Samant S, and Zhang B. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. Journal of Clinical Investigation. (2020) 130 (7), 3528-3542

29. Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, and Lesniak MS. HIF-1α acts as a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Reports. (2019) 27 (1), 226-237. e4

28. Rashidi A, Miska J, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, and Lesniak MS. GCN2 is Essential for CD8+ T-cell Survival and Function in Murine Models of Malignant Glioma. Cancer Immunology Immunotherapy. (2020) 69 (1), 81-94

27. Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, and Lesniak MS. HIF-1α acts as a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Reports. (2019) 27 (1), 226-237. e4

26. Wu M, Miska J*, Xiao T, Zhang P, Kane JR, Balyasnikova IV, Chandler JP, Horbinski CM and Lesniak MS. Race influences survival in glioblastoma patients with KPS≥ 80 and associates with genetic markers of retinoic acid metabolism. Journal of Neuro-Oncology. (2019) 1-10

25. Zhang P, Miska J, Lee-Chang C, A Rashidi, Panek WK, An S, Zannikou M, Lopez-Rosas A, Han Y, Xiao T, Pituch, KC, Kanojia D, Balyasnikova IB, and Lesniak MS. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. PNAS (2019) 116 (47), 23714-23723

24. Lee-Chang C, Rashidi A, Miska J, Zhang P, Panek WK, Pituch, KC, Hou D, Xiao T, Fischietti M, Kang SJ, Appin, Horbinski C, Platanias LC, Lopez-Rosas A, Han Y, Balyasnikova IB, and Lesniak MS. Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunology Research. (2019) 0240.2019

23. Wu C, Muroski ME, Miska J, Lee-Chang C, Shen Y, Rashidi A, Zhang P, Xiao T, Han Y, Lopez-Rosas A, Chen Y and Lesniak MS. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine: Nanotechnology, Biology and Medicine. (2019) 16, 126-137

22. Cordero A, Kanojia D, Miska J, Panek WK, Xiao A, Han Y, Bonamici N, Zhou W, Xiao T, Wu M, Ahmed, AU, Lesniak MS. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis. Oncogene. (2019)

21. Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baiswala S, Park CH, Saathoff MR, Warnke L, Xiao T, Lesniak MS, James CD, Meltzer H, Tryba AK, Ahmed AU. Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma. Journal of Neuroscience. (2019) 1589-18

20. Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS. Current state of clinical trials in breast cancer brain metastases. Neuro-Oncology Practice. (2019)

19. Miska J, Lui JB, Toomer KH, Devarajan P, Cai X, Houghton JM, Lopez DM, Abreu MT, Wang G, and Chen Z. Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines. Journal of Experimental Medicine. (2018) 215(3): 841-858

18. Panek WK, Pituch KC, Miska J, Kim JW, Rashidi A, Kanojia D, Lopez-Rosas A, Han Y, Yu D, Lee-Chang C, Kane JR, Zhang P, Cordero A, and Lesniak MS. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model. Molecular Neurobiology. (2018) 1-9

17. Kaverina NV, Kadagidze ZG, Borovjagin AV, Karseladze AI, Kim CK, Lesniak MS, Miska J, Zhang P, Baryshnikova MA, Xiao T, Ornelles D, Cobbs C, Khramtsov A and Ulasov IV. Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. Oncogene. (2018) 37:6069–6082

16. Kim JW, Kane JR, Panek WK, Young JS, Rashidi A, Yu D, Kanojia D, Hasan T, Miska J, Gomez-Lim MA, Ulasoz IU, Balyasnikova IV, Ahmed AU, Wainwright DA and Lesniak MS. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model. Neurotherapeutics (2018) 15(4): 1127-1138

15. Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Lesniak MS, Gottschalk S, and Balyasnikova IV. Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma. Molecular Therapy. (2018) 26(4):986-995

14. Kim JW & Miska J*, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IB, and Lesniak MS. A Comparative Study of Replication-Incompetent and-Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Molecular Therapy-Oncolytics. (2017) 5:97-104

13. Muroski ME & Miska J*,Chang AL, Zheng P, Rashidi A, Moore H, Han Yand Lesniak MS. Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. Scientific Reports. (2017).

12. Miska J, Rashidi A, Chang AL, Muroski M, Han Y, Zhang L, and Lesniak MS. Anti-GITR Therapy Promotes Immunity Against Malignant Glioma. Cancer Immunology Immunotherapy (2016) 65 (12), 1555-1567

11. `Chang AL, Miska J, Wainwright DA, Dey M, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, Han Y, Wu M, Zhang L, Ahmed AU, and Lesniak MS. Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells. Cancer Research (2016).

10. Miska J, Lesniak MS (2015) Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme. Ebiomedicine 2 (8):774-775. doi:10.1016/j.ebiom.2015.08.022

9. Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias A, Zhang LJ, Qiao J, Lesniak MS. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. Journal of Immunology. (2015) 195(1):367-76.

8. Kane JR, Miska J, Young JS, Kanojia D, Kim JW, Lesniak MS. Sui generis: Gene therapy and delivery systems for the treatment of glioblastoma. Neuro-Oncology (2015) Suppl 2:ii24-ii36. doi: 10.1093/neuonc/nou355.

7. Kanojia D, Morshed RA, Zhang L, Miska J, Qiao J, Kim JW, Pytel P, Balyasnikova IV, Ahmed AU, Lesniak MS. βIII-tubulin regulates breast cancer metastasis to the brain. Molecular Cancer Therapeutics (2015) 14(5):1152-61.

6. M Kim JW, Kane JR, Young JS, Chang AL, Kanojia D, Morshed RA, Miska J, Ahmed AU, Balyasnikova IV, Han Y, Zhang LJ, Curiel DT, Lesniak MS (2015) A Genetically Modified Adenoviral Vector with a Phage Display-Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma. Hum Gene Ther 26 (9):635-646. doi:10.1089/hum.2015.008

5. Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, Nettlebeck D, Han Y, Zhang L, and Lesniak MS. Intratumoral Oncolytic Adenoviral Treatment Modulates the Glioma Microenvironment and Facilitates Systemic Tumor-Antigen Specific T cell Therapy. Oncoimmunlogy (2015) 2;4(8):e1022302.

4. Miska J, Abdulreda MH, Devarajan P, Lui JB, Suzuki J, Pileggi A, et al. Real-time immune cell interactions in target tissue during autoimmune-induced damage and graft tolerance. J Exp Med (2014) 211:441–56.

3. Devarajan P, Miska J, Lui JB, Swieboda D, Chen Z. Opposing Effects of CTLA4 Insufficiency on Regulatory versus Conventional T Cells in Autoimmunity Converge on Effector Memory in Target Tissue. J Immunol (2014) Nov 1;193(9):4368-80. doi: 10.4049/jimmunol.1400876

2. Miska J, Devarajan P, and Chen Z. The immunological identity of tumor: self-implications. Oncoimmunology (2013) 2:e23794.10.4161/onci.23794

1.   Miska J, Bas E, Devarajan P, Chen Z. Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self. Eur J Immunol (2012) 42:2584–2596.